Plant Name: Ostericum grosseserratum
Taxonomic Information:
Plant ID: NPO2953
Plant Latin Name: Ostericum grosseserratum
Taxonomy Genus: Ostericum
Taxonomy Family: Apiaceae
Plant External Links:
NCBI TaxonomyDB:
182415
Plant-of-the-World-Online:
845576-1
Used in Medicines:
Unknown.
Geographical Distribution:
China; Mongolia; South Africa
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| GAA; | |
| CA2; CA12; CA9; CA14; | |
| PPARA; | |
| ALOX15; USP2; BRCA1; POLB; | |
| CASP1; CASP7; | |
| AHR; TP53; | |
| KMT2A; | |
| HTT; NPC1; LMNA; FABP3; FABP5; FABP4; RAB9A; HBB; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.788E-11 | 1.066E-06 | CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, HBB |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.293E-09 | 4.694E-06 | CYP1A1, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.633E-09 | 1.805E-05 | ALOX15, CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, HBB |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.358E-09 | 2.022E-05 | CA12, CA14, CA2, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.331E-09 | 2.032E-05 | CA12, CA14, CA2, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.959E-08 | 4.296E-05 | AHR, CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.639E-08 | 4.953E-05 | CYP1A1, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.921E-08 | 7.163E-05 | CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, HBB |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.232E-08 | 9.434E-05 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.060E-07 | 1.099E-04 | FABP3, FABP4, FABP5, FFAR4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.778E-07 | 2.086E-04 | CYP1A1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 7.407E-07 | 4.887E-04 | ALOX15, CA2, CYP1A1, FABP4, KMT2A, NPC1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 1.994E-06 | 1.085E-03 | AHR, KMT2A, PPARA, USP2 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 2.538E-06 | 1.316E-03 | AHR, ALOX15, BRCA1, CA2, CYP1A1, CYP1B1, FABP5, GAA, HTT, KMT2A, LMNA, POLB, PPARA, SMN1, SMN2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.822E-06 | 1.365E-03 | CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, NPC1 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.383E-06 | 2.211E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0006915; apoptotic process | 6.516E-06 | 2.628E-03 | AHR, BRCA1, CASP1, CASP7, HTT, KMT2A, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.151E-06 | 2.717E-03 | CYP1A1, CYP1B1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 9.266E-06 | 3.363E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.737E-05 | 5.667E-03 | CA2, CA9, CASP1, CYP1A1, FABP3, FFAR1, NPC1, TP53 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 2.353E-05 | 7.217E-03 | GAA, HTT, KMT2A, NPC1, PPARA, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 2.561E-05 | 7.537E-03 | BRCA1, CASP1, CASP7, FABP3, FFAR4, NPC1, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.841E-05 | 8.141E-03 | CA12, CA2, CA9 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 3.088E-05 | 8.734E-03 | AHR, PPARA, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.266E-08 | 1.038E-06 | CA12, CA2, CA9, CA14 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.436E-06 | 1.486E-04 | CYP2C9, CYP2D6, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 4.337E-06 | 1.486E-04 | FABP3, FABP4, FABP5, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.647E-06 | 1.773E-04 | CYP2C9, CYP1A1, CYP1B1, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.969E-05 | 4.058E-04 | CYP2C9, CYP2D6, ALOX15, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.322E-05 | 2.167E-04 | CYP2C9, ALOX15, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.320E-04 | 1.546E-03 | CYP2C9, ALOX15, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.814E-04 | 1.860E-03 | CYP2C9, CYP2D6, CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA9; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; |
| NA: NA | Edema | NA | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
